Michalak A, Butterworth R F
Neuroscience Research Unit, University of Montreal, Quebec, Canada.
Hepatology. 1997 Mar;25(3):631-5. doi: 10.1002/hep.510250323.
There is increasing evidence that alterations of glutamatergic function are implicated in the pathogenesis of central nervous system consequences of acute liver failure. The aim of the study was to assess the integrity of glutamate receptors in the brain in experimental ischemic liver failure using quantitative receptor autoradiography and the selective ligands [3H]MK801 (for N-methyl-D-aspartate [NMDA] sites), [3H]5-fluorowillardiine (for non-NMDA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid [AMPA] subclass sites), and [3H]kainate (for non-NMDA, kainate subclass sites). At coma stages of encephalopathy, a selective loss of up to 60% of binding sites for the kainate- and AMPA-receptor ligands was observed in cerebral cortical and hippocampal structures as well as in the hypothalamus and cerebellum. The finding of a selective loss of AMPA sites at coma stages of encephalopathy in this model of acute liver failure is consistent with previous electrophysiological reports of inhibition of AMPA-mediated neuronal depolarization resulting from exposure of hippocampal neurons to millimolar concentrations of ammonia. On the other hand, the present study showed that binding sites for the NMDA-receptor ligand [3H]MK801 at coma stages of encephalopathy in acute liver failure were within normal limits in all brain structures examined. NMDA sites are uniquely neuronal, whereas kainate and AMPA sites are localized on both neurons and astrocytes. Therefore, the selective loss of non-NMDA sites in acute liver failure may also reflect astrocytic changes in this condition. Because astrocytic glutamate receptors are implicated in K+ and neurotransmitter reuptake, alterations in their density could result in altered neuronal excitability and thus be responsible for the neurological dysfunction characteristic of hepatic encephalopathy in acute liver failure.
越来越多的证据表明,谷氨酸能功能的改变与急性肝衰竭中枢神经系统后果的发病机制有关。本研究的目的是使用定量受体放射自显影和选择性配体[3H]MK801(用于N-甲基-D-天冬氨酸[NMDA]位点)、[3H]5-氟威拉蒂因(用于非NMDA,α-氨基-3-羟基-5-甲基-4-异恶唑丙酸[AMPA]亚类位点)和[3H]海人酸(用于非NMDA,海人酸亚类位点)来评估实验性缺血性肝衰竭时大脑中谷氨酸受体的完整性。在肝性脑病的昏迷阶段,在大脑皮质、海马结构以及下丘脑和小脑中观察到海人酸和AMPA受体配体的结合位点选择性丧失高达60%。在该急性肝衰竭模型中,肝性脑病昏迷阶段AMPA位点选择性丧失的发现与先前的电生理报告一致,该报告表明海马神经元暴露于毫摩尔浓度的氨会抑制AMPA介导的神经元去极化。另一方面,本研究表明,急性肝衰竭肝性脑病昏迷阶段NMDA受体配体[3H]MK801的结合位点在所有检查的脑结构中均在正常范围内。NMDA位点仅存在于神经元中,而海人酸和AMPA位点则定位于神经元和星形胶质细胞上。因此,急性肝衰竭中非NMDA位点的选择性丧失也可能反映了这种情况下星形胶质细胞的变化。由于星形胶质细胞谷氨酸受体与K+和神经递质的再摄取有关,其密度的改变可能导致神经元兴奋性改变,从而导致急性肝衰竭肝性脑病的神经功能障碍特征。